We are live on ! Find out more
EWTX icon

Edgewise Therapeutics
EWTX

90 hedge funds and large institutions have $594M invested in Edgewise Therapeutics in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 16

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

17% more capital invested

Capital invested by funds: $505M → $594M (+$88.4M)

2.18% less ownership

Funds ownership: 107.31% → 105.13% (-2.2%)

4% less funds holding

Funds holding: 94 → 90 (-4)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

50% less call options, than puts

Call options by funds: $25K | Put options by funds: $50K

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
1.45%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
11
Increased
44
Reduced
16
Closed
14
Calls
$25K
Puts
$50K
Net Calls
-$25K
Net Calls Change
-$25K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$9.4M
2
BlackRock
BlackRock
New York
+$7.11M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.74M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.17M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.86M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.6M
2
MB
MPM BioImpact
Massachusetts
-$2.99M
3
WP
Woodline Partners
California
-$1.69M
4
EI
EAM Investors
California
-$1.21M
5
Millennium Management
Millennium Management
New York
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$2.31M +$19.6K +2,088 +0.8%
TCM
27
Tekla Capital Management
Massachusetts
$1.74M – – –
HS
28
HighVista Strategies
Massachusetts
$1.68M +$788K +84,018 +81%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.14M +$298K +31,834 +33%
ECM
30
ExodusPoint Capital Management
New York
$1.05M +$4.05K +432 +0.4%
N
31
Nuveen
North Carolina
$954K -$46K -4,907 -4%
Renaissance Technologies
32
Renaissance Technologies
New York
$694K +$181K +19,300 +33%
Morgan Stanley
33
Morgan Stanley
New York
$539K -$417K -44,436 -42%
PHP
34
Parkman Healthcare Partners
Connecticut
$473K +$27.1K +2,896 +6%
Bank of America
35
Bank of America
North Carolina
$470K +$369K +39,347 +297%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$456K +$64.2K +6,845 +16%
AA
37
ALPS Advisors
Colorado
$384K +$402K +42,906 New
Millennium Management
38
Millennium Management
New York
$377K -$1.09M -116,286 -73%
QPW
39
Quantum Private Wealth
Florida
$333K +$37K +3,950 +12%
TI
40
Trexquant Investment
Connecticut
$286K +$138K +14,752 +85%
Jane Street
41
Jane Street
New York
$285K +$125K +13,288 +71%
DekaBank Deutsche Girozentrale
42
DekaBank Deutsche Girozentrale
Germany
$265K – – –
MAM
43
Martingale Asset Management
Massachusetts
$258K +$34.2K +3,648 +14%
GCP
44
GSA Capital Partners
United Kingdom
$236K -$9.57K -1,021 -4%
JP Morgan Chase
45
JP Morgan Chase
New York
$217K +$42.4K +4,520 +23%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$216K +$75.8K +8,090 +50%
MIM
47
MetLife Investment Management
New Jersey
$209K – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$205K +$95.6K +10,200 +80%
PP
49
PDT Partners
New York
$172K -$41.5K -4,422 -19%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$164K +$172K +18,340 New
1
2
3 4 5

EWTX Hedge Fund Activity: Q4 2022 in Review

90 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q4 2022, worth a combined $594M — up 17% from $505M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of EWTX and 11 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 44 added.

The largest buyer was Goldman Sachs, adding an estimated $9.4M. The largest seller was Janus Henderson Group, cutting an estimated $15.6M.

  • 90 institutional investors held Edgewise Therapeutics (EWTX) as of Q4 2022, down from 94 in Q3 2022.
  • Funds reported $594M of Edgewise Therapeutics stock for Q4 2022, up 17% quarter-over-quarter.
  • 11 funds opened new Edgewise Therapeutics positions in Q4 2022 and 14 closed out, a net change of -3 holders.
  • The largest Edgewise Therapeutics buyer in Q4 2022 was Goldman Sachs, an estimated $9.4M added.
  • The largest Edgewise Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2022.